Update information

Update information

July 2018: Sections 1 and 2 of the guidance were updated because the European Medicines Agency restricted the use of atezolizumab for untreated urothelial carcinoma to adults with high levels of PD-L1.

ISBN: 978-1-4731-2735-7

  • National Institute for Health and Care Excellence (NICE)